TD Asset Management Inc. trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 152,030 shares of the company’s stock after selling 4,570 shares during the period. TD Asset Management Inc. owned approximately 0.17% of Neurocrine Biosciences worth $9,316,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the company. FMR LLC increased its holdings in shares of Neurocrine Biosciences by 9.8% during the 2nd quarter. FMR LLC now owns 13,211,023 shares of the company’s stock valued at $607,707,000 after purchasing an additional 1,180,874 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Neurocrine Biosciences by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 6,922,294 shares of the company’s stock valued at $318,426,000 after purchasing an additional 186,329 shares in the last quarter. Janus Henderson Group PLC purchased a new position in shares of Neurocrine Biosciences during the 2nd quarter valued at approximately $246,888,000. BB Biotech AG increased its holdings in shares of Neurocrine Biosciences by 7.7% during the 2nd quarter. BB Biotech AG now owns 3,446,552 shares of the company’s stock valued at $158,541,000 after purchasing an additional 245,000 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of Neurocrine Biosciences by 20.7% during the 2nd quarter. Franklin Resources Inc. now owns 3,378,615 shares of the company’s stock valued at $155,416,000 after purchasing an additional 579,900 shares in the last quarter.
In other news, insider Haig P. Bozigian sold 26,250 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $1,575,000.00. Following the completion of the sale, the insider now owns 144,601 shares of the company’s stock, valued at $8,676,060. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Christopher Flint Obrien sold 52,817 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $57.50, for a total transaction of $3,036,977.50. Following the sale, the insider now directly owns 101,790 shares of the company’s stock, valued at approximately $5,852,925. The disclosure for this sale can be found here. In the last three months, insiders sold 150,710 shares of company stock valued at $9,758,593. 4.80% of the stock is owned by insiders.
Several equities analysts have recently weighed in on the stock. Cowen reaffirmed an “outperform” rating and set a $65.00 target price (up from $60.00) on shares of Neurocrine Biosciences in a report on Wednesday, August 9th. Deutsche Bank reaffirmed a “buy” rating and set a $79.00 target price on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Citigroup reaffirmed a “buy” rating and set a $79.00 target price on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Finally, Oppenheimer lifted their target price on shares of Neurocrine Biosciences from $70.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday, November 2nd. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. Neurocrine Biosciences currently has a consensus rating of “Buy” and an average price target of $78.88.
Shares of Neurocrine Biosciences, Inc. (NBIX) opened at $73.60 on Monday. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37. Neurocrine Biosciences, Inc. has a 1-year low of $37.35 and a 1-year high of $75.98.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same period in the previous year, the firm posted ($0.43) EPS. sell-side analysts forecast that Neurocrine Biosciences, Inc. will post -1.74 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “TD Asset Management Inc. Decreases Holdings in Neurocrine Biosciences, Inc. (NBIX)” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://transcriptdaily.com/2017/12/04/td-asset-management-inc-decreases-holdings-in-neurocrine-biosciences-inc-nbix.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.